These levels of weight loss begin to approach the results seen with bariatric surgery, positioning Mounjaro as a true game-changer in the non-surgical treatment of obesity
Eccogene will present Phase 1b data for elecoglipron (AZD5004/ECC5004), our investigational oral small-molecule GLP-1 receptor agonist, in a late-breaking poster presentation at the American Diabetes Associations 2026 Scientific Sessions
You are also receiving help from a team that is committed to helping you achieve your desired health outcomes
"I truly believe that when these amylin [drugs] launch, we can have that, what I've described as an iPhone moment, because patients are so aware of the experience they have on the GLP-1s, and once you launch a new modality that gives you a better experience, people will queue up to get access to that new weight loss medication rather than staying on the more cumbersome medicines," said Zealand CEO Adam Steensberg
District Court for the Northern District of California
David McConda, and Dr
